Summary
Signal counts
Assets tracked: 3
Watchlist assets: 2
Registry stop assets: 0
Sponsor overview
CSPC Megalith Biopharmaceutical Co.,.
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT06989671 | https://clinicaltrials.gov/study/NCT06775236 | https://clinicaltrials.gov/study/NCT07251062
Assets
Linked programs
- JMT101: Operational Burden Signal (2/5)
- SYS6010 jnjection: Operational Burden Signal (2/5)
- SYS6010+SG001+ physician's choice (Capecitabine or 5-FU): Low Signal (1/5)